Amgen Inc (AMGN)
Amgen Inc (AMGN) carries a ŷRobot AI score of 52 out of 100. The model's fair value estimate is $429.90, 0.6% below the last close of $432.49. The chart signal reads Sell.
| Metric | AMGN |
|---|---|
| AI score | 52 / 100 |
| Chart signal | Sell |
| Fair value estimate | $429.90 |
| Upside to fair value | -0.6% |
| Previous close | $432.49 |
| P/E | 26.17 |
| Price / sales | 5.72 |
| Market cap | $230.37B |
| EPS | 15.56 |
| Revenue growth | 11.7% |
| 1-year price change | 7.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about AMGN
Is AMGN overvalued or undervalued right now?
As of Oct 16, 2026, ŷRobot's fair-value model estimates Amgen Inc (AMGN) at $429.90 against a last close of $432.49, implying 0.6% downside to the model's estimate.
Is AMGN's chart signal bullish or bearish?
The chart-signal model classifies AMGN as Neutral as of Oct 16, 2026, with a signal score of -0.12 on a -1 to 1 scale.
What is AMGN's ŷRobot AI score?
AMGN scores 52 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
Is AMGN stock expensive on P/E and P/S?
AMGN trades at 26.2 times earnings and 5.7 times sales as of Oct 16, 2026.
What does AMGN's seasonal forecast show?
ŷRobot's seasonal forecast curve for AMGN reads -0.3% at 30 days, +2.5% at 90 days, and +7.4% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is AMGN growing?
Amgen Inc's revenue growth is +11.7% and free-cash-flow growth is +3.2% on the latest reported figures.
AMGN chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.